Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a US-based clinical stage biotechnology company, announced on Wednesday that its clinical development partner, AgonOx, Inc, a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumour cells, has, in partnership with Providence Cancer Institute, completed the site initiation visit and can commence patient accrual for their collaborative clinical trial of PH-762.
The clinical trial is intended to evaluate the safety and the potential for improved therapeutic benefit from the administration of Phio's PH-762 treated 'double positive' (DP) CD8 tumour infiltrating lymphocytes (TILs) in subjects with melanoma and other advanced solid tumours. The trial will be carried out at Providence Cancer Institute in Portland, Oregon, by principal investigator Brendan Curti, MD, Medical Oncologist and Robert W Franz endowed chair for Clinical Research at the Earle A Chiles Research Institute, a division of Providence.
Phio Pharmaceuticals received FDA approval to start a clinical trial of intratumoral PH-762 in subjects with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The trial is likely to start in the second half of 2023.
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis
Avacta completes sixth dose escalation in AVA6000 Phase 1 trial
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Pfizer's LITFULO gains EC approval for treating severe alopecia areata in adolescents and adults
Orexo AB submits OX124 New Drug Application to FDA
Allos Pharma expands Arbaclofen's intellectual property rights
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Lantern Pharma gains FDA IND clearance for LP-284 to treat non-Hodgkin's lymphoma
RedHill receives FDA sNDA approval for Talicia with improved dosing regimen
Gedeon Richter and Sumitomo Pharma receive positive European regulatory opinion for RYEQO
Innocan names Dr Joseph V. Pergolizzi Jr to Scientific Advisory Board
Oscotec and ADEL receive approval from FDA for IND application of ADEL-Y01
argenx SE receives positive CHMP opinion for SC efgartigimod in gMG
First Wave BioPharma secures exclusive global licence for Capeserod from Sanofi